These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 23812726

  • 1. Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment.
    Dokduang H, Juntana S, Techasen A, Namwat N, Yongvanit P, Khuntikeo N, Riggins GJ, Loilome W.
    Tumour Biol; 2013 Dec; 34(6):3519-28. PubMed ID: 23812726
    [Abstract] [Full Text] [Related]

  • 2. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
    Yothaisong S, Dokduang H, Techasen A, Namwat N, Yongvanit P, Bhudhisawasdi V, Puapairoj A, Riggins GJ, Loilome W.
    Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
    [Abstract] [Full Text] [Related]

  • 3. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F, Grabinski N, Grottke A, Windhorst S, Nörz D, Carstensen L, Staufer K, Hofmann BT, Diehl F, David K, Schumacher U, Nashan B, Jücker M.
    Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
    [Abstract] [Full Text] [Related]

  • 4. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
    Yokoi K, Kobayashi A, Motoyama H, Kitazawa M, Shimizu A, Notake T, Yokoyama T, Matsumura T, Takeoka M, Miyagawa SI.
    Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327
    [Abstract] [Full Text] [Related]

  • 5. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
    Blechacz BR, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ.
    Hepatology; 2009 Dec; 50(6):1861-70. PubMed ID: 19821497
    [Abstract] [Full Text] [Related]

  • 6. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H, Zhang J, Zhang Y, Feng Q, Wang H, Li G, Jiang W, Li X.
    Gene; 2019 May 25; 698():50-60. PubMed ID: 30822475
    [Abstract] [Full Text] [Related]

  • 7. Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway.
    Wang Y, Yu H, Xie X, Deng T, Ye L, Wu L, Ding X, Yang Z, Zhu Q, Li J, Zheng Y, Yu Z, Chen G.
    Oncogene; 2021 Jun 25; 40(25):4324-4337. PubMed ID: 34079085
    [Abstract] [Full Text] [Related]

  • 8. Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion.
    Menakongka A, Suthiphongchai T.
    World J Gastroenterol; 2010 Feb 14; 16(6):713-22. PubMed ID: 20135719
    [Abstract] [Full Text] [Related]

  • 9. Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors.
    Ewald F, Nörz D, Grottke A, Hofmann BT, Nashan B, Jücker M.
    Invest New Drugs; 2014 Dec 14; 32(6):1144-54. PubMed ID: 25152244
    [Abstract] [Full Text] [Related]

  • 10. TCF21 inhibits tumor-associated angiogenesis and suppresses the growth of cholangiocarcinoma by targeting PI3K/Akt and ERK signaling.
    Duan HX, Li BW, Zhuang X, Wang LT, Cao Q, Tan LH, Qu GF, Xiao S.
    Am J Physiol Gastrointest Liver Physiol; 2019 Jun 01; 316(6):G763-G773. PubMed ID: 30920845
    [Abstract] [Full Text] [Related]

  • 11. Atractylodin inhibited the migration and induced autophagy in cholangiocarcinoma cells via PI3K/AKT/mTOR and p38MAPK signalling pathways.
    Acharya B, Chaijaroenkul W, Na-Bangchang K.
    J Pharm Pharmacol; 2021 Aug 12; 73(9):1191-1200. PubMed ID: 33885818
    [Abstract] [Full Text] [Related]

  • 12. Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells.
    Jinawath A, Akiyama Y, Sripa B, Yuasa Y.
    J Cancer Res Clin Oncol; 2007 Apr 12; 133(4):271-8. PubMed ID: 17294242
    [Abstract] [Full Text] [Related]

  • 13. Overexpression of ECM1 contributes to migration and invasion in cholangiocarcinoma cell.
    Xiong GP, Zhang JX, Gu SP, Wu YB, Liu JF.
    Neoplasma; 2012 Apr 12; 59(4):409-15. PubMed ID: 22489696
    [Abstract] [Full Text] [Related]

  • 14. Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2.
    Liu R, Zhao R, Zhou X, Liang X, Campbell DJ, Zhang X, Zhang L, Shi R, Wang G, Pandak WM, Sirica AE, Hylemon PB, Zhou H.
    Hepatology; 2014 Sep 12; 60(3):908-18. PubMed ID: 24700501
    [Abstract] [Full Text] [Related]

  • 15. Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells.
    Elsner A, Lange F, Fitzner B, Heuschkel M, Krause BJ, Jaster R.
    World J Gastroenterol; 2014 Jun 28; 20(24):7914-25. PubMed ID: 24976727
    [Abstract] [Full Text] [Related]

  • 16. Leptin enhances cholangiocarcinoma cell growth.
    Fava G, Alpini G, Rychlicki C, Saccomanno S, DeMorrow S, Trozzi L, Candelaresi C, Venter J, Di Sario A, Marzioni M, Bearzi I, Glaser S, Alvaro D, Marucci L, Francis H, Svegliati-Baroni G, Benedetti A.
    Cancer Res; 2008 Aug 15; 68(16):6752-61. PubMed ID: 18701500
    [Abstract] [Full Text] [Related]

  • 17. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
    Fiorio Pla A, Brossa A, Bernardini M, Genova T, Grolez G, Villers A, Leroy X, Prevarskaya N, Gkika D, Bussolati B.
    BMC Cancer; 2014 Dec 12; 14():939. PubMed ID: 25494980
    [Abstract] [Full Text] [Related]

  • 18. Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma.
    Boonjaraspinyo S, Boonmars T, Wu Z, Loilome W, Sithithaworn P, Nagano I, Pinlaor S, Yongvanit P, Nielsen PS, Pairojkul C, Khuntikeo N.
    Tumour Biol; 2012 Oct 12; 33(5):1785-802. PubMed ID: 22733151
    [Abstract] [Full Text] [Related]

  • 19. Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.
    Honma Y, Shimizu S, Takehara T, Harada M.
    J Gastroenterol; 2014 Mar 12; 49(3):517-26. PubMed ID: 23543326
    [Abstract] [Full Text] [Related]

  • 20. Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma.
    Zhang GF, Qiu L, Yang SL, Wu JC, Liu TJ.
    Biosci Rep; 2020 Mar 27; 40(3):. PubMed ID: 32140709
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.